Lin Yang

Lin Yang

Auto-generated profile, based on publicly available information

Lin Yang

Institute of Lung Health and Immunity (LHI), Helmholtz Munich, Comprehensive Pneumology Center (CPC-M), Member of the German Center for Lung Research (DZL), Munich, Germany

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LYLin Yang
Lin Yang
HKHuijuan Kuang
Huijuan Kuang
WZWanyi Zhang
Wanyi Zhang
ZAZoraida P. Aguilar
Zoraida P. Aguilar
HWHua Wei
Hua Wei
Hengyi XuHengyi Xu
Hengyi Xu
Nanoparticles (NPs) size, surface functionalization, and concentration were claimed to contribute to distribution and toxicity outcomes of NPs in vivo. However, intrinsic chemical compositions of NPs caused inconsistent biodistribution and toxic profiles which attracted little attention. In this study, silver nanoparticles (AgNPs) and gold nanoparticles (AuNPs) were used to determine the biodistribution, toxickinetic, and genotoxicity variances in murine animals. The results demonstrated AgNPs and AuNPs were primarily deposited in the mononuclear phagocyte system (MPS) such as the liver and spleen. In particular, AuNPs seemed to be prominently stored in the liver, whereas AgNPs preferentially accumulated in more organs such as the heart, lung, kidney, etc. Also, the circulation in the blood and fecal excretions showed higher AgNPs contents in comparison with the AuNPs. Measurements of the mouse body and organ mass, hematology and biochemistry evaluation, and histopathological examinations indicated slight toxic difference between the AgNPs and AuNPs over a period of two months. RT-qPCR data revealed that AgNPs induced greater changes in gene expression with relevance to oxidative stress, apoptosis, and ion transport. Our observations proved that the NPs chemical composition played a critical role in their in vivo biodistribution and toxicity.

6 November 2014 in Nanoscale
Verified
Journal Article
Closed access
PDF file
LYLin Yang
Lin Yang
HKHuijuan Kuang
Huijuan Kuang
WZWanyi Zhang
Wanyi Zhang
ZAZoraida P. Aguilar
Zoraida P. Aguilar
YXYonghua Xiong
Yonghua Xiong
HWHua Wei
Hua Wei
In spite of the immense benefits from iron oxide magnetic nanoparticles (IOMNs), there is scanty information regarding their metabolic activities and toxicity in vivo. In this study, we investigated the size dependent in vivo biodistribution, toxicokinetics, and toxicity and gene expression changes of various sizes of carboxyl coated IOMNs (diameters of 10, 20, 30, and 40 nm). Our findings demonstrated that the various sizes of IOMNs accumulated primarily in the liver and spleen on the first day post-injection. Interestingly, size dependent biodistribution and transport were observed: the smallest IOMNs (10 nm) showed the highest uptake by the liver, whereas the largest IOMNs (40 nm) showed the highest uptake by the spleen. Moreover, the IOMNs with the smallest size (10 nm) were cleared faster from the liver and kidneys, but more readily entered the brain and the uterus. IOMNs with the largest size (40 nm) accumulated more readily but were easily eliminated in the spleen. However, the level of iron in the heart decreased in all IOMN exposed groups. In addition, blood biochemistry, hematological analyses and histological examination demonstrated that there was no apparent acute toxicity caused by IOMNs in mice. However, smaller IOMNs (10 nm and 20 nm) more effectively changed the expression level of sensitive genes related to oxidant stress, iron transport, metabolic process, apoptosis, and others.

6 December 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
NLNiklas J. Lang
Niklas J. Lang
JGJanine Gote-Schniering
Janine Gote-Schniering
DPDiana Porras-Gonzalez
Diana Porras-Gonzalez
LYLin Yang
Lin Yang
LSLaurens De Sadeleer
Laurens De Sadeleer
HSHerbert B. Schiller
Herbert B. Schiller
Pulmonary fibrosis develops as a consequence of failed regeneration after injury. Analyzing mechanisms of regeneration and fibrogenesis directly in human tissue has been hampered by the lack of organotypic models and analytical techniques. In this work, we coupled ex vivo cytokine and drug perturbations of human precision-cut lung slices (hPCLS) with single-cell RNA sequencing and induced a multilineage circuit of fibrogenic cell states in hPCLS. We showed that these cell states were highly similar to the in vivo cell circuit in a multicohort lung cell atlas from patients with pulmonary fibrosis. Using micro-CT–staged patient tissues, we characterized the appearance and interaction of myofibroblasts, an ectopic endothelial cell state, and basaloid epithelial cells in the thickened alveolar septum of early-stage lung fibrosis. Induction of these states in the hPCLS model provided evidence that the basaloid cell state was derived from alveolar type 2 cells, whereas the ectopic endothelial cell state emerged from capillary cell plasticity. Cell-cell communication routes in patients were largely conserved in hPCLS, and antifibrotic drug treatments showed highly cell type–specific effects. Our work provides an experimental framework for perturbational single-cell genomics directly in human lung tissue that enables analysis of tissue homeostasis, regeneration, and pathology. We further demonstrate that hPCLS offer an avenue for scalable, high-resolution drug testing to accelerate antifibrotic drug development and translation.

1 November 2016 in Journal of Hazardous Materials
Verified
Journal Article
Closed access
HKHuijuan Kuang
Huijuan Kuang
PYPengfei Yang
Pengfei Yang
LYLin Yang
Lin Yang
ZAZoraida P. Aguilar
Zoraida P. Aguilar
Hengyi XuHengyi Xu
Hengyi Xu

23 February 2020 in Expert Opinion on Drug Delivery
Verified
Journal Article
Closed access
SEStephan Ehrmann
Stephan Ehrmann
OSOtmar Schmid
Otmar Schmid
CDChantal Darquenne
Chantal Darquenne
BRBarbara Rothen-Rutishauser
Barbara Rothen-Rutishauser
JSJosue Sznitman
Josue Sznitman
NHNathalie Heuzé-Vourc'h
Nathalie Heuzé-Vourc'h
Introduction: Pulmonary drug delivery is a complex field of research combining physics which drive aerosol transport and deposition and biology which underpins efficacy and toxicity of inhaled drugs. A myriad of preclinical methods, ranging from in-silico to in-vitro, ex-vivo and in-vivo, can be implemented. Areas covered: The present review covers in-silico mathematical and computational fluid dynamics modelization of aerosol deposition, cascade impactor technology to estimated drug delivery and deposition, advanced in-vitro cell culture methods and associated aerosol exposure, lung-on-chip technology, ex-vivo modeling, in-vivo inhaled drug delivery, lung imaging and longitudinal pharmacokinetic analysis. Expert opinion: No single pre-clinical model can be advocated; all methods are fundamentally complementary and should be implemented based on benefits and drawbacks to answer specific scientific questions. The overall best scientific strategy depends, among others, on the product under investigations, inhalation device design, disease of interest, clinical patient population, previous knowledge. Pre-clinical testing is not to be separated from clinical evaluation, as small proof-of-concept clinical studies or conversely large scale clinical big data may inform pre-clinical testing. The extend of expertise required for such translational research is unlikely to be found in one single laboratory calling for the setup of multinational large-scale research consortiums.

22 July 2019 in Advanced Functional Materials
Verified
Journal Article
Closed access
PDF file
ADAli Doryab
Ali Doryab
STSinem Tas
Sinem Tas
MTMehmet Berat Taskin
Mehmet Berat Taskin
LYLin Yang
Lin Yang
AHAnne Hilgendorff
Anne Hilgendorff
OSOtmar Schmid
Otmar Schmid